Business Description
Compare
Compare
Traded in other countries / regions
543635.India Index Membership
NIFTY 500 IPO Date
2022-10-19Description
Piramal Pharma Ltd is a pharmaceutical company, providing end-to-end pharma services to customers and a portfolio of differentiated pharma products across a domestic and international distribution network. It operates under three business verticals; an integrated contract development and manufacturing (CDMO) business providing Active pharmaceutical ingredients (APIs), Finished dosage forms (FDFs), biologics, and vaccines among other products; the other two business verticals include a complex hospital generics business, and an India consumer healthcare business, selling over-the-counter products in India. Geographically, the company generates maximum revenue from North America and the rest from Europe, India, Japan, and other markets.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.12 | |||||
| Equity-to-Asset | 0.52 | |||||
| Debt-to-Equity | 0.6 | |||||
| Debt-to-EBITDA | 2.94 | |||||
| Interest Coverage | 1.49 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 3.07 | |||||
| Beneish M-Score | -2.5 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 8.7 | |||||
| 3-Year EBITDA Growth Rate | 6 | |||||
| 3-Year EPS without NRI Growth Rate | -39.4 | |||||
| 3-Year Book Growth Rate | 3.8 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 127.82 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 12.87 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 74.13 | |||||
| 9-Day RSI | 60.75 | |||||
| 14-Day RSI | 54.01 | |||||
| 3-1 Month Momentum % | -8.53 | |||||
| 6-1 Month Momentum % | -20.12 | |||||
| 12-1 Month Momentum % | 30.31 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.54 | |||||
| Quick Ratio | 0.93 | |||||
| Cash Ratio | 0.15 | |||||
| Days Inventory | 261.13 | |||||
| Days Sales Outstanding | 83.91 | |||||
| Days Payable | 165.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.05 | |||||
| Dividend Payout Ratio | 0.16 | |||||
| Forward Dividend Yield % | 0.07 | |||||
| 5-Year Yield-on-Cost % | 0.05 | |||||
| 3-Year Average Share Buyback Ratio | -2.8 | |||||
| Shareholder Yield % | -0.68 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 64.69 | |||||
| Operating Margin % | 6.87 | |||||
| Net Margin % | 1 | |||||
| EBITDA Margin % | 18.06 | |||||
| FCF Margin % | 2.49 | |||||
| ROE % | 1.14 | |||||
| ROA % | 0.59 | |||||
| ROIC % | 1.02 | |||||
| 3-Year ROIIC % | -6.41 | |||||
| ROC (Joel Greenblatt) % | 10.78 | |||||
| ROCE % | 7.63 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 300.88 | |||||
| Forward PE Ratio | 142.22 | |||||
| PE Ratio without NRI | 300.88 | |||||
| Price-to-Owner-Earnings | 9300 | |||||
| PS Ratio | 2.94 | |||||
| PB Ratio | 3.33 | |||||
| Price-to-Tangible-Book | 6.69 | |||||
| Price-to-Free-Cash-Flow | 120.28 | |||||
| Price-to-Operating-Cash-Flow | 30.73 | |||||
| EV-to-EBIT | 37.53 | |||||
| EV-to-EBITDA | 18.99 | |||||
| EV-to-Revenue | 3.43 | |||||
| EV-to-FCF | 137.69 | |||||
| Price-to-GF-Value | 1.29 | |||||
| Price-to-Graham-Number | 9.46 | |||||
| Earnings Yield (Greenblatt) % | 2.66 | |||||
| FCF Yield % | 0.84 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers